Traditional sterilization filters (0.2-micron rated) work well for buffer and small molecule drugs. However, they are often incompatible with mammalian cell culture broths because:
The Parenteral Drug Association (PDA) Technical Report No. 82 (TR 82) addresses Low Endotoxin Recovery (LER) in biologics, providing a scientific consensus on the mechanism, hold-time studies, and mitigation techniques. The report, which is currently undergoing revision, outlines methods to manage the masking of endotoxin activity in complex drug formulations. For more details, visit PDA Technical Report No. 82 Parenteral Drug Association Technical Report No. 82: Low Endotoxin Recovery | PDA
during sudden, uncontrolled thawing procedures. Standard Operating Procedures (SOPs) and Training pda technical report 82 pdf
PDA Technical Report No. 82 (TR 82) provides comprehensive guidance on Low Endotoxin Recovery (LER), a phenomenon where endotoxins in biopharmaceutical formulations become masked and undetected by standard LAL assays. The 128-page report covers scientific mechanisms, hold-time study design, and mitigation strategies, including 12 case studies on root causes and demasking. The report defines LER as failing to recover more than 50% of spiked endotoxin activity over time. Purchase the official report at the PDA Bookstore . Technical Report No. 82: Low Endotoxin Recovery | PDA
TR 82 outlines considerations for choosing the right freezing and storage equipment. This includes: Traditional sterilization filters (0
| Area | Action | |------|--------| | | Include LER assessment using spiked samples stored under representative conditions (time, temperature, container). | | Sample Handling | Test within 4 hours of sampling when possible. If delay occurs, justify storage conditions. | | Neutralization | Evaluate alternatives to standard dilution (e.g., high dilution, Mg++ addition, heating) to dissociate complexes. | | Container Evaluation | Screen primary containers (pre-filled syringes, vials) for endotoxin adsorption. |
PDA Technical Report No. 82 is far more than a technical document; it is a pivotal piece of pharmaceutical literature that has reshaped quality control practices for biologics. It provides the framework for understanding, investigating, and mitigating a complex analytical challenge that sits at the intersection of formulation science, analytical chemistry, and patient safety. The report, which is currently undergoing revision, outlines
A quick Google search might reveal links claiming to offer a free PDF. As a professional, you should be aware of three major risks:
PDA TR 82 is a substantial document. The full report is and provides a structured, scientific framework for addressing LER from root cause to remediation. Its key sections and objectives can be broken down as follows:
Explain the .
A major reason for validation failure? The lab-scale low pH hold does not mimic the manufacturing scale. TR-82 insists on matching the "ramp rate" (the time it takes to go from neutral pH to target low pH). In large bioreactors, a 60-second ramp might take 5-10 minutes. The report provides acceptance criteria for scaling mixers and pumps to ensure your lab data is predictive.